Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

msh id	COM:SEQUANAMEDICAL
symbol	SEQUA
name	Sequana Medical NV
homepage url	https://www.sequanamedical.com
country	BE
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	62
crunchbase url	-
linkedin url	-
founders	-

market cap	43.58M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.04
growth cost of revenue	22.78
growth depreciation and amortization	1.12
growth ebitda	-0.03
growth ebitda ratio	-0.33
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-6.78
growth gross profit ratio	-8.5

COM:SEQUANAMEDICAL

Sequana Medical NV

Last Close

0.89

21/11 16:36

Market Cap

40.33M

Beta: -

Volume Today

41.75K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	32.61M
cost of revenue	32.61M
depreciation and amortization	713.64K
ebitda	-31.13M
ebitda ratio	-40.49
eps	-1.32
eps diluted	-1.32
operating expenses	27.36M
operating income	-31.84M
operating income ratio	-41.42

accounts receivables	-586.24K
capital expenditure	-767.62K
cash at beginning of period	20.38M
cash at end of period	2.79M
inventory	2.48M
working capital ttm	7.94M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-